ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Macrophages in oncoviral infections: from immune regulators to therapeutic targets.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHuman oncoviruses infect host cells and drive tumorigenesis. Macrophages, as key innate immune cells, exhibit functional heterogeneity and polarization plasticity. They are broadly classified into proinflammatory M1 and anti-inflammatory M2 states, which determine their role in immunity and tissue homeostasis.
methodsWe summarized the recent experimental and clinical studies on the interactions between macrophages and the major oncoviruses, including Epstein-Barr virus (EBV), Kaposi's Sarcoma-associated herpesvirus (KSHV), hepatitis B virus (HBV), hepatitis C virus (HCV), human T-cell leukemia virus type 1 (HTLV-1), and human papillomavirus (HPV). We focus on how viral proteins, non-coding RNAs, and extracellular vesicles reprogram macrophage functions and discuss emerging macrophage-targeted therapeutic strategies.
resultsOncoviruses drive macrophages toward pro-tumor M2 or dysfunctional M1 states by altering cytokine secretion, activating signaling pathways, such as cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) and nuclear factor kappa B (NF-κB), and reprogramming metabolic pathways. New therapeutic strategies targeting macrophages, including polarization modulation, bispecific antibodies, nanomedicine delivery systems, and immune checkpoint strategies, show promise in enhancing antiviral and antitumor immunity.
conclusionMacrophages can sense various oncoviruses and play a role in oncovirus infection, chronic inflammation, and virus-driven tumorigenesis. Potential therapeutic strategies targeting macrophages offer new avenues for the precision treatment of oncovirus-associated diseases.
Indexed as
Identifiers
42323450What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.